”We thank our principal owners and other existing shareholders for the continued strong support, and would also like to welcome new shareholders to AlzeCure. We also thank them for their trust in AlzeCure and our research, as well as their interest in continuing to support and participate in our world-leading research in Alzheimer’s and pain”
AlzeCure achieved an oversubscribed rights issue, July 2025
